BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 7, 2005
View Archived Issues
Millennium updates pipeline progress
Read More
Locteron begins phase I study for chronic hepatitis C
Read More
Satraplatin begins phase II study in metastatic breast cancer
Read More
Tm Bioscience develops upper respiratory viral panel
Read More
GTC Biotherapeutics and LEO Pharma enter agreement for ATryn
Read More
Positive outcome for BEMA-fentanyl in comparative pharmacokinetics study
Read More
Alnylam seeks clearance for phase I study of ALN-RSV01 for RSV
Read More
Antiviral FluCide-I begins preclinical studies
Read More
DOR BioPharma to acquire Gastrotech Pharma
Read More
NF-676: novel and potent use-dependent blocker of RyR1
Read More
SL-650155 reveals effects of serotonin in models of amnesia
Read More
ACTOplus met available in U.S. for type 2 diabetes
Read More
Novel agents for the treatment of neurological disorders disclosed in recent patents
Read More
Recent patents report compounds with potential use in the treatment of respiratory disorders
Read More
New treatments for cancer covered in recent patents
Read More
In vitro effects of anti-TNF-alpha agents on apoptosis and cytotoxicity
Read More
AT-001 reported effective in the treatment of rheumatoid arthritis
Read More
AmPrbetaCD: a novel anthrax lethal toxin inhibitor
Read More
Update on the therapeutic benefits of quetiapine in psychological disorders
Read More
Acadia presents a new potent, orally available, isoform-selective RARbeta2 agonist
Read More
Phase I data on tgAAC94 in inflammatory arthritis
Read More
Clinical evidence confirms transdermal selegiline is safe in patients with major depression
Read More